Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Sumitomo Pharma America, Inc.
This is a Phase 2, randomized, double-blind, parallel-group, multicenter, outpatient study evaluating the efficacy and safety of SEP 225289 in adults with ADHD using 2 oral dosages (4 or 8 mg SEP 225289 once daily \[QD\]) versus placebo over a 4 week treatment period.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted